sorafenib has been researched along with olaparib in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (olaparib) | Trials (olaparib) | Recent Studies (post-2010) (olaparib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,313 | 172 | 1,258 |
| Protein | Taxonomy | sorafenib (IC50) | olaparib (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 1.538 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.02 | |
| Cholinesterase | Homo sapiens (human) | 0.0035 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.1741 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.02 | |
| Protein mono-ADP-ribosyltransferase PARP6 | Homo sapiens (human) | 1.8 | |
| Protein mono-ADP-ribosyltransferase PARP15 | Homo sapiens (human) | 7.6216 | |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 5.2854 | |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | 5.1143 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 2.3349 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 0.001 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.1866 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.4087 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.1315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Akber Ansari, S; Arote, R; Chhajed, S; Pathan, SK; Patil, R; Sangshetti, J; Shinde, DB | 1 |
| Gong, YP; He, ZX; Ma, LY; Zhang, X; Zhao, W | 1 |
| Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R | 1 |
| Guan, XY; Kong, FE; Lin, JX; Liu, M; Loong, JHC; Ma, NF; Ma, S; Qi, L; Xi, SY; Yan, Q; Yang, XD; Yuan, YF; Zhang, Y; Zhao, Y | 1 |
3 review(s) available for sorafenib and olaparib
| Article | Year |
|---|---|
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.
Topics: Humans; Phthalazines | 2019 |
Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Protein Binding; Protein Conformation; Proto-Oncogene Proteins c-met; Pyridazines; Pyrophosphatases; Structure-Activity Relationship | 2021 |
Antiangiogenic therapy in oncology: current status and future directions.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
2 other study(ies) available for sorafenib and olaparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chromatin; DNA Damage; Drug Resistance, Neoplasm; Embryonic Stem Cells; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sorafenib; Transcriptome | 2021 |